JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
Volume 17, Issue 3 (2025)
Iran J War Public Health 2025, 17(3): 279-291 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2025/06/6 | Accepted: 2025/07/28 | Published: 2025/08/10
Received: 2025/06/6 | Accepted: 2025/07/28 | Published: 2025/08/10
How to cite this article
Wennas O, Haji Ghasem Kashani M, Abiri E, Altememy D. Apoptotic Effect of some Schiff's Base Compounds on HepG2 and Adipose Tissue Stem cells. Iran J War Public Health 2025; 17 (3) :279-291
URL: http://ijwph.ir/article-1-1680-en.html
URL: http://ijwph.ir/article-1-1680-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq
2- Department of Cellular and Molecular Biology, Faculty of Biology and Institute of Biological Sciences, Damghan University, Damghan, Iran
3- Department of Pharmaceutics, Faculty of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq
2- Department of Cellular and Molecular Biology, Faculty of Biology and Institute of Biological Sciences, Damghan University, Damghan, Iran
3- Department of Pharmaceutics, Faculty of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq
Abstract (716 Views)
Aims: Schiff bases are compounds known for their anti-cancer properties. The combination of Schiff bases with metals enhances their anticancer effects. The current study was conducted to determine the apoptotic effect of Schiff base compounds derived from 2-hydroxynaphthaldehyde and 2-chloroethylamine, along with manganese complexes, on HepG2 cells compared to mesenchymal stem cells at the Damghan Faculty of Chemistry, Iran.
Materials & Methods: In this experimental study, three Schiff base compounds, naph-Br, naph(br)2Mn, and naph(br)2Ni, were used to investigate anticancer properties on HepG2 cancer cells and compare them with adipose tissue stem cells. HepG2 and adipose tissue-derived stem cells were treated for 24 hours with these compounds at concentrations of 100, 200, 300, 400, 500, 600, and 700µM. Cell proliferation and survival were evaluated using hemocytometry, MTT, and Ki-67 immunocytochemistry methods.
Findings: Schiff base compounds reduced the proliferation rate of HepG2 cancer cells and adipose tissue-derived stem cells at concentrations of 200, 300, 400, and 500µM, while increasing the rate compared to the control group.
Conclusion: Schiff base compounds inhibit the proliferation of cancer cells and induce apoptosis at multiple concentrations, demonstrating their versatility and efficacy in combating cancer.
Materials & Methods: In this experimental study, three Schiff base compounds, naph-Br, naph(br)2Mn, and naph(br)2Ni, were used to investigate anticancer properties on HepG2 cancer cells and compare them with adipose tissue stem cells. HepG2 and adipose tissue-derived stem cells were treated for 24 hours with these compounds at concentrations of 100, 200, 300, 400, 500, 600, and 700µM. Cell proliferation and survival were evaluated using hemocytometry, MTT, and Ki-67 immunocytochemistry methods.
Findings: Schiff base compounds reduced the proliferation rate of HepG2 cancer cells and adipose tissue-derived stem cells at concentrations of 200, 300, 400, and 500µM, while increasing the rate compared to the control group.
Conclusion: Schiff base compounds inhibit the proliferation of cancer cells and induce apoptosis at multiple concentrations, demonstrating their versatility and efficacy in combating cancer.
Keywords:
HepG2 Cells [MeSH], Adipose Tissue Stem Cells (ASC) [MeSH], Schiff Base [MeSH], Apoptosis [MeSH], Cancer [MeSH], Stem Cells [MeSH], Rat [MeSH]
References
1. Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, et al. Deciphering STAT3 signaling potential in hepatocellular carcinoma: Tumorigenesis, treatment resistance, and pharmacological significance. Cell Mol Biol Lett. 2023;28(1):33. [Link] [DOI:10.1186/s11658-023-00438-9]
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. [Link] [DOI:10.3322/caac.21262]
3. Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Anaraki KT, Motahhary M, et al. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Environ Res. 2023;233:116458. [Link] [DOI:10.1016/j.envres.2023.116458]
4. Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, et al. STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. Biomed Pharmacother. 2023;158:114168. [Link] [DOI:10.1016/j.biopha.2022.114168]
5. Hashemi M, Esbati N, Rashidi M, Gholami S, Raesi R, Bidoki SS, et al. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Transl Oncol. 2024;40:101846. [Link] [DOI:10.1016/j.tranon.2023.101846]
6. Steck SE, Murphy EA. Dietary patterns and cancer risk. Nat Rev Cancer. 2020;20(2):125-38. [Link] [DOI:10.1038/s41568-019-0227-4]
7. Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021;148(1):38-47. [Link] [DOI:10.1002/ijc.33185]
8. Hashemi M, Nazdari N, Gholamiyan G, Paskeh MDA, Jafari AM, Khodaei E, et al. EZH2 as a potential therapeutic target for gastrointestinal cancers. Pathol Res Pract. 2024;253:154988. [Link] [DOI:10.1016/j.prp.2023.154988]
9. Yarhusseini A, Sharifzadeh L, Delpisheh A, Veisani Y, Sayehmiri F, Sayehmiri K. Survival rate of esophageal carcinoma in Iran-A systematic review and meta-analysis. Iran J Cancer Prev. 2014;7(2):61-5. [Link]
10. Hashemi M, Daneii P, Zandieh MA, Raesi R, Zahmatkesh N, Bayat M, et al. Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response. Noncoding RNA Res. 2023;9(1):84-104. [Link] [DOI:10.1016/j.ncrna.2023.11.005]
11. Chhaniwal N, Li C, Wang J, Qiang G, Qi T, Maher H. Hepatocellular carcinoma: Review of current treatment with a focus on transarterial chemoembolization and radiofrequency ablation. Open J Radiol. 2015;5(1):50-8. [Link] [DOI:10.4236/ojrad.2015.51009]
12. Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008;26(17):2800-5. [Link] [DOI:10.1200/JCO.2007.15.5945]
13. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286(1):9-14. [Link] [DOI:10.1016/j.canlet.2008.10.040]
14. Rafati A, Ghaleh HEG, Azarabadi A, Masoudi MR, Afrasiab E, Alvanegh AG. Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus. Transpl Immunol. 2022;75:101721. [Link] [DOI:10.1016/j.trim.2022.101721]
15. Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, et al. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis. Pathol Res Pract. 2023;251:154902. [Link] [DOI:10.1016/j.prp.2023.154902]
16. Huang GJ, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: Their biology and role in regenerative medicine. J Dent Res. 2009;88(9):792-806. [Link] [DOI:10.1177/0022034509340867]
17. Raesi R, Zabolian A, Hasani Sadi F, Javanshir S, Salimimoghadam S, Jung YY, et al. Circular RNAs (circRNAs) in cancer metastasis: Molecular interactions and possible therapeutic targets. In: Non-coding RNA transcripts in cancer therapy: Pre-clinical and clinical implications. Hackensack: World Scientific; 2023. p. 247-81. [Link] [DOI:10.1142/9789811267390_0010]
18. Sheng G. The developmental basis of mesenchymal stem/stromal cells (MSCs). BMC Dev Biol. 2015;15:44. [Link] [DOI:10.1186/s12861-015-0094-5]
19. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells-current trends and future prospective. Biosci Rep. 2015;35(2):e00191. [Link] [DOI:10.1042/BSR20150025]
20. Lee JH, Park CH, Chun KH, Hong SS. Effect of adipose-derived stem cell-conditioned medium on the proliferation and migration of B16 melanoma cells. Oncol Lett. 2015;10(2):730-6. [Link] [DOI:10.3892/ol.2015.3360]
21. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: Characteristics and clinical applications. Folia Histochem Cytobiol. 2006;44(4):215-30. [Link]
22. De Melo SM, Bittencourt S, Ferrazoli EG, Da Silva CS, Da Cunha FF, Da Silva FH, et al. The anti-tumor effects of adipose tissue mesenchymal stem cell transduced with HSV-Tk gene on U-87-driven brain tumor. PLoS One. 2015;10(6):e0128922. [Link] [DOI:10.1371/journal.pone.0128922]
23. Freese KE, Kokai L, Edwards RP, Philips BJ, Sheikh MA, Kelley J, et al. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: A systematic review. Cancer Res. 2015;75(7):1161-8. [Link] [DOI:10.1158/0008-5472.CAN-14-2744]
24. Hashemi M, Roshanzamir SM, Orouei S, Daneii P, Raesi R, Zokaee H, et al. Shedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma. Noncoding RNA Res. 2024;9(2):508-22. [Link] [DOI:10.1016/j.ncrna.2024.02.002]
25. Ahn JO, Lee HW, Seo KW, Kang SK, Ra JC, Youn HY. Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One. 2013;8(9):e74897. [Link] [DOI:10.1371/journal.pone.0074897]
26. Yu X, Su B, Ge P, Wang Z, Li S, Huang B, et al. Human adipose derived stem cells induced cell apoptosis and s phase arrest in bladder tumor. Stem Cells Int. 2015;2015:619290. [Link] [DOI:10.1155/2015/619290]
27. Raesi R, Saghari S, Bassiri F, Motahhary M, Salimimoghadam S, Coskun A, et al. Exosomal circular RNAs (circRNAs) in cancer progression and diagnosis. In: Non-coding RNA transcripts in cancer therapy: Pre-clinical and clinical implications. Hackensack: World Scientific; 2023. p. 319-56. [Link] [DOI:10.1142/9789811267390_0012]
28. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845. [Link] [DOI:10.1155/2014/150845]
29. Lawen A. Apoptosis-an introduction. Bioessays. 2003;25(9):888-96. [Link] [DOI:10.1002/bies.10329]
30. Shaye ZA, Jabbari Noghabi F, Mostafavian Z, Raesi R. Investigation of cancer risk factors in the lifestyle of medical students at Mashhad University of Medical Sciences. Arch Adv Biosci. 2023;14(1):E41697. [Link]
31. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol. 2004;14(4):184-93. [Link] [DOI:10.1016/j.tcb.2004.03.002]
32. Wu M, Ding H, Fisher D. Apoptosis: Molecular mechanisms. In: eLS. Hoboken: John Wiley & Sons; 2001. [Link] [DOI:10.1038/npg.els.0001150]
33. Chaichian S, Nikfar B, Bidgoli SA, Moazzami B. The role of genistein and its derivatives in ovarian cancer: New perspectives for molecular mechanisms and clinical applications. Curr Med Chem. 2025;32(5):907-22. [Link] [DOI:10.2174/0109298673251713231019091910]
34. Cairrão F, Domingos PM. Apoptosis: Molecular mechanisms. In: eLS. Hoboken: John Wiley & Sons; 2010. [Link] [DOI:10.1002/9780470015902.a0001150.pub2]
35. Banerjee S, Mondal S, Chakraborty W, Sen S, Gachhui R, Butcher RJ, et al. Syntheses, X-ray crystal structures, DNA binding, oxidative cleavage activities and antimicrobial studies of two Cu (II) hydrazone complexes. Polyhedron. 2009;28(13):2785-93. [Link] [DOI:10.1016/j.poly.2009.05.071]
36. Zuo J, Bi C, Fan Y, Buac D, Nardon C, Daniel KG, et al. Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. J Inorg Biochem. 2013;118:83-93. [Link] [DOI:10.1016/j.jinorgbio.2012.10.006]
37. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M. Vanadium-an element of atypical biological significance. Toxicol Lett. 2004;150(2):135-43. [Link] [DOI:10.1016/j.toxlet.2004.01.009]
38. Tülüce Y, Hussein AI, Koyuncu I, Kilic A, Durgun M. The effect of a bis‐structured Schiff base on apoptosis, cytotoxicity, and DNA damage of breast cancer cells. J Biochem Mol Toxicol. 2022;36(10):e23148. [Link] [DOI:10.1002/jbt.23148]
39. Hassan A, Nassar A, Ahmed Y, Elkmash A. Synthesis, characterization and biological evaluation of binuclear Fe (III), Co (II), Ni (II), Cu (II) and Zn (II) complexes with schiff base (E)-4-[(Hydroxyl Phenylimino) Methyl] Benzene-1, 2-Diol. Int J Pharm Sci Res. 2012;3(7):2243. [Link] [DOI:10.1007/s12010-012-9709-5]
40. Noser AA, Abdelmonsef AH, El-Naggar M, Salem MM. New amino acid Schiff bases as anticancer agents via potential mitochondrial complex I-associated hexokinase inhibition and targeting AMP-protein kinases/mTOR signaling pathway. Molecules. 2021;26(17):5332. [Link] [DOI:10.3390/molecules26175332]
41. Crans DC, Smee JJ, Gaidamauskas E, Yang L. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem Rev. 2004;104(2):849-902. [Link] [DOI:10.1021/cr020607t]
42. Mangamamba T, Ganorkar M, Swarnabala G. Characterization of complexes synthesized using Schiff base ligands and their screening for toxicity two fungal and one bacterial species on rice pathogens. Int J Inorg Chem. 2014;2014. [Link] [DOI:10.1155/2014/736538]
43. Chhikara BS, Parang K. Global cancer statistics 2022: The trends projection analysis. Chem Biol Lett. 2023;10(1):451. [Link]
44. Schulz WA. Molecular biology of human cancers. Cham: Springer; 2023. [Link] [DOI:10.1007/978-3-031-16286-2]
45. Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22(5):259-79. [Link] [DOI:10.1038/s41568-022-00441-w]
46. Padma VV. An overview of targeted cancer therapy. BioMedicine. 2015;5(4):19. [Link] [DOI:10.7603/s40681-015-0019-4]
47. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7(11):3314-24. [Link]
48. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 1997;57(23):5246-53. [Link]
49. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: The past, present, and future. J Thorac Oncol. 2008;3(8):917-28. [Link] [DOI:10.1097/JTO.0b013e318180270b]
50. Capuano G, Daniele B, Gaeta GB, Gallo C, Perrone F. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology. 1998;28(3):751-5. [Link] [DOI:10.1002/hep.510280322]
51. Venook AP, Papandreou C, Furuse J, Ladrón De Guevara L. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist. 2010;15(S4):5-13. [Link] [DOI:10.1634/theoncologist.2010-S4-05]
52. Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther. 2015;9(5):352-62. [Link] [DOI:10.5582/ddt.2015.01047]
53. Gerber DE. Targeted therapies: A new generation of cancer treatments. Am Fam Physician. 2008;77(3):311-9. [Link]
54. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5. [Link] [DOI:10.2217/17460751.3.1.1]
55. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452-4. [Link] [DOI:10.1038/197452a0]
56. Konno M, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, Nishikawa S, et al. Adipose‐derived mesenchymal stem cells and regenerative medicine. Dev Growth Differ. 2013;55(3):309-18. [Link] [DOI:10.1111/dgd.12049]
57. Chen HT, Lee MJ, Chen CH, Chuang SC, Chang LF, Ho ML, et al. Proliferation and differentiation potential of human adipose‐derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med. 2012;16(3):582-92. [Link] [DOI:10.1111/j.1582-4934.2011.01335.x]
58. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem cells. 2009;27(10):2624-35. [Link] [DOI:10.1002/stem.194]
59. Koc O, Lazarus H. Mesenchymal stem cells: Heading into the clinic. Bone Marrow Transplant. 2001;27(3):235-9. [Link] [DOI:10.1038/sj.bmt.1702791]
60. Ramdasi S, Sarang S, Viswanathan C. Potential of mesenchymal stem cell based application in cancer. Int J Hematol Oncol Stem Cell Res. 2015;9(2):95-103. [Link]
61. Murtaza G, Mumtaz A, Khan FA, Ahmad S, Azhar S, Najam-Ul-Haq M, et al. Recent pharmacological advancements in schiff bases: A review. Acta Pol Pharm. 2014;71(4):531-5. [Link]
62. Abu-Dief AM, Mohamed IM. A review on versatile applications of transition metal complexes incorporating Schiff bases. Beni Suef Univ J Basic Appl Sci. 2015;4(2):119-33. [Link] [DOI:10.1016/j.bjbas.2015.05.004]
63. Amir MK, Khan S, Rehman ZU, Shah A, Butler IS. Anticancer activity of organotin (IV) carboxylates. INORGANICA CHIMICA ACTA. 2014;423(B):14-25. [Link] [DOI:10.1016/j.ica.2014.07.053]
64. Amer S, El-Wakiel N, El-Ghamry H. Synthesis, spectral, antitumor and antimicrobial studies on Cu (II) complexes of purine and triazole Schiff base derivatives. J Mol Struct. 2013;1049:326-35. [Link] [DOI:10.1016/j.molstruc.2013.06.059]
65. Jevtović V, Ivković S, Kaisarević S, Kovačević R. Anticancer activity of new copper (II) complexes incorporating a pyridoxal-semicarbazone ligand. Contemp Mater. 2010;1(2):133-7. [Link] [DOI:10.5767/anurs.cmat.100102.en.133J]
66. Gwaram NS, Hassandarvish P. Synthesis, characterization and anticancer studies of some morpholine derived Schiff bases and their metal complexes. J Appl Pharm Sci. 2014;4(10):75-80. [Link] [DOI:10.7324/JAPS.2014.401014]